GTR Home > Tests > NeXT Dx

Overview

Test name

Help

NeXT Dx

Purpose of the test

Help

This is a clinical test intended for Help: Prognostic, Therapeutic management

Condition

Help

1 condition tested. Click Indication tab for more information.

How to order

Help

Order URL Help: https://www.personalis.com/products/next-dx-test/

Specimen source

Paraffin block

Methodology

Help
Molecular Genetics
IMicrosatellite instability testing (MSI)
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • NeXT Dx
RRNA analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • NeXT Dx
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • NeXT Dx

Summary of what is tested

247 genes and variants, 2 analytes. Click Methodology tab for more information.

Genes

Analytes

  • Microsatellite Instability
  • Tumor mutational burden

Clinical utility

Help

Guidance for management

Citations
  • PMIDs 27993330, 30227640, 28481359, 28481359, 27782854, 26028255, 28835386, 29337640, 29658845, 25409260

Clinical validity

Help

The Personalis NeXT Dx Test, based on the NeXT platform, should be considered when personalized therapeutic guidance is sought for patients with cancer. The NeXT Dx test is indicated for use on solid tumors (FFPE), where samples are reviewed and selected by a pathologist as the most representative block for the patient’s diagnosis. The intended use of the NeXT Dx test is in-line with the rationale for molecular testing of cancers described in “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists” (PMID 27993330). Specifically, the NeXT Dx test should be used in situations where a more complete knowledge of the molecular alteration status of a cancer may assist in making clinical diagnosis and treatment decisions, determining prognosis, and determining patient eligibility for clinical trials.

Citations
  • Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. - PubMed ID: 27993330

Test services

Help
  • Result interpretation

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center